January 2018                                                                                                 View this email in your browser

Here's to a great 2018!

Hope your year has started off with a bang!
Registration is open for Synapse Academy,
our online CPD.
Cost: R700 for access to 30 CPD points. 
Contact us at to register, or click here to contact us. 
2017 Synapse Academy Members
Articles will remain available on the website
if you would still like to complete those activities. 
Synapse Conference

20 - 22 July

Clarens Golf and Lifestyle Estate

Some of our speakers
Prof André Venter (Pediatrician)
Dr Jaco Cilliers (Neurologist)
Dr Claude Botha (Psychiatrist)
Dr Vicky Nicolaou (Endocrinologist)
Martelie Burger (Optometrist)
R4500 for 3 days
17 CPD points will be applied for.

Contact us at
or follow us on Facebook
for more information
Back to School
South Africa allocates 15% of its national budget to education, a bigger proportion than the US or
the UK.  However, a Global Competitiveness Report by the World Economic Forum ranked SA's primary education system as 126th in the world and higher education as 134th, out of 138 selected countries.
This was your favourite Facebook post this month. 
Like our page for a regular dose of funny, useful, informative, intriguing and beautiful content.

What's New?
Glaucoma drug.

Rhopressa is a ROCK-inhibitor, or Rho-associated coil–forming protein kinase inhibitor, approved by the FDA a few weeks ago.
Synapse Academy subscribers will already know from Volume 5, Issue 1, Glaucoma that it increases outflow through the trabecular meshwork and drops episcleral venous pressure. 
It reduced IOP by 28% during trials and appears particularly good for patients who start treatment with lower pressures. Side effects are similar to the prostaglandin analogues: Hyperemia and tenderness. Also vortex keratopathy, pain on instillation
and conjunctival hemorrhage may occur.

Red eyes? 

Glaucoma medication Lumigan, as a side effect, makes lashes darker, thicker and longer, so the clever folk at Allergan brought out a lower dose version and now we have Latisse?
Well, brimonidine (Alphagan P) lowers IOP too but at low doses it
whitens eyes without dropping IOP, which is exactly why there is no patent issue with B&L's Lumify (0.025% brimonidine), recently FDA-approved. It is better than other vasoconstrictor-based red eye drops because there is no rebound redness when treatment is stopped. It works within a minute and lasts for up to 8 hours.
See? Perfectly white!
Until next month!

Copyright © 2018, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp